Primary Aldosteronism and Ischemic Heart Disease

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Jun 9

PMID 35677685

Authors

Shivaraj Patil

Chaitanya Rojulpote

Aman Amanullah

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease, in particular ischemic heart disease is a major cause of morbidity and mortality worldwide. Primary aldosteronism is the leading cause of secondary hypertension, yet commonly under diagnosed, and represents a major preventable risk factor. In contrast to historical teaching, recent studies have shown that excess aldosterone production is associated with increased burden of ischemic heart disease disproportionate to the effects caused by hypertension alone. Aldosterone through its genomic and non-genomic actions exerts various detrimental cardiovascular changes contributing to this elevated risk. Recognition of primary hyperaldosteronism and understanding the distinctive pathophysiology of ischemic heart disease in primary aldosteronism is crucial to develop strategies to improve outcomes.

Citing Articles

Global Burden of Early-Onset Ischemic Heart Disease, 1990 to 2019.

Liu X, Wu Y, Li F, Qi X, Niu L, Wu Y JACC Adv. 2025; 4(1):101466.

PMID: 39811756 PMC: 11731480. DOI: 10.1016/j.jacadv.2024.101466.

First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures.

Manso J, Pedron M, Mondin A, Censi S, Pennelli G, Galuppini F Int J Mol Sci. 2024; 25(2).

PMID: 38255827 PMC: 10815259. DOI: 10.3390/ijms25020754.

Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid Cancer LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway.

Pan R, Zhao J, Yao J, Gao Y, Liao L Comb Chem High Throughput Screen. 2024; 27(16):2419-2432.

PMID: 38173060 DOI: 10.2174/0113862073286006231228070738.

References

Savard S, Amar L, Plouin P, Steichen O . Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013; 62(2):331-6. DOI: 10.1161/HYPERTENSIONAHA.113.01060. View

Peng K, Liao H, Chan C, Lin W, Yang S, Tsai Y . Presence of Subclinical Hypercortisolism in Clinical Aldosterone-Producing Adenomas Predicts Lower Clinical Success. Hypertension. 2020; 76(5):1537-1544. DOI: 10.1161/HYPERTENSIONAHA.120.15328. View

Gerards J, Heinrich D, Adolf C, Meisinger C, Rathmann W, Sturm L . Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. J Clin Endocrinol Metab. 2019; 104(8):3192-3202. DOI: 10.1210/jc.2019-00299. View

OGara P, Kushner F, Ascheim D, Casey Jr D, Chung M, de Lemos J . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 61(4):e78-e140. DOI: 10.1016/j.jacc.2012.11.019. View

Luther J . Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014; 91:54-60. PMC: 4252580. DOI: 10.1016/j.steroids.2014.08.016. View

Lorell B, Carabello B . Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000; 102(4):470-9. DOI: 10.1161/01.cir.102.4.470. View

Vasan R, Evans J, Larson M, Wilson P, Meigs J, Rifai N . Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004; 351(1):33-41. DOI: 10.1056/NEJMoa033263. View

Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y . Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan. Hypertension. 2018; 71(3):530-537. DOI: 10.1161/HYPERTENSIONAHA.117.10263. View

Mensah G, Roth G, Fuster V . The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. J Am Coll Cardiol. 2019; 74(20):2529-2532. DOI: 10.1016/j.jacc.2019.10.009. View

10.

Rosendorff C, Lackland D, Allison M, Aronow W, Black H, Blumenthal R . Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015; 131(19):e435-70. PMC: 8365343. DOI: 10.1161/CIR.0000000000000207. View

11.

Mills K, Bundy J, Kelly T, Reed J, Kearney P, Reynolds K . Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016; 134(6):441-50. PMC: 4979614. DOI: 10.1161/CIRCULATIONAHA.115.018912. View

12.

Mignano A, Pitruzzella V, Arnone G, Arnone M, Rotolo A, Assennato P . Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. J Cardiovasc Med (Hagerstown). 2013; 15(1):27-32. DOI: 10.2459/JCM.0b013e328364129c. View

13.

Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A . Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012; 60(3):618-24. DOI: 10.1161/HYPERTENSIONAHA.112.197111. View

14.

Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A . Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013; 98(12):4826-33. DOI: 10.1210/jc.2013-2805. View

15.

Udell J, Morrow D, Braunwald E, Swedberg K, Bode C, Rifai N . Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. Clin Chem. 2013; 59(6):959-67. DOI: 10.1373/clinchem.2012.199729. View

16.

Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and.... Hypertension. 2003; 42(5):1050-65. DOI: 10.1161/01.HYP.0000102971.85504.7c. View

17.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. DOI: 10.1056/NEJMoa030207. View

18.

Urbanet R, Nguyen Dinh Cat A, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C . Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension. 2015; 66(1):149-57. DOI: 10.1161/HYPERTENSIONAHA.114.04981. View

19.

Bulluck H, Frohlich G, Nicholas J, Mohdnazri S, Gamma R, Davies J . Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. Am Heart J. 2019; 211:60-67. PMC: 6483973. DOI: 10.1016/j.ahj.2019.02.005. View

20.

Hajar R . Diabetes as "Coronary Artery Disease Risk Equivalent": A Historical Perspective. Heart Views. 2017; 18(1):34-37. PMC: 5448252. DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_37_17. View